| Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation A Saito, T Irie, R Suzuki, T Maemura, H Nasser, K Uriu, Y Kosugi, ... Nature 602 (7896), 300-306, 2022 | 481 | 2022 |
| The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance I Kimura, Y Kosugi, J Wu, J Zahradnik, D Yamasoba, EP Butlertanaka, ... Cell reports 38 (2), 2022 | 189 | 2022 |
| Classical NF-κB pathway is responsible for APOBEC3B expression in cancer cells W Maruyama, K Shirakawa, H Matsui, T Matsumoto, H Yamazaki, ... Biochemical and biophysical research communications 478 (3), 1466-1471, 2016 | 67 | 2016 |
| SARS-CoV-2 spike P681R mutation, a hallmark of the Delta variant, enhances viral fusogenicity and pathogenicity A Saito, T Irie, R Suzuki, T Maemura, H Nasser, K Uriu, Y Kosugi, ... BioRxiv, 2021.06. 17.448820, 2021 | 56 | 2021 |
| SARS-CoV-2 spike P681R mutation enhances and accelerates viral fusion A Saito, H Nasser, K Uriu, Y Kosugi, T Irie, K Shirakawa, K Sadamasu, ... | 53 | 2021 |
| Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma Y Ochi, Y Kazuma, N Hiramoto, Y Ono, S Yoshioka, N Yonetani, ... Annals of hematology 96, 1-8, 2017 | 42 | 2017 |
| SARS-CoV-2 Omicron spike mediated immune escape and tropism shift B Meng, IATM Ferreira, A Abdullahi, N Goonawardane, A Saito, I Kimura, ... BioRxiv, 2021.12. 17.473248, 2021 | 35 | 2021 |
| Genotype to phenotype japan (G2P-Japan) consortium. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 delta P681R mutation A Saito, T Irie, R Suzuki, T Maemura, H Nasser, K Uriu, Y Kosugi, ... Nature 10, 2021 | 35 | 2021 |
| Endogenous APOBEC3B overexpression constitutively generates DNA substitutions and deletions in myeloma cells H Yamazaki, K Shirakawa, T Matsumoto, S Hirabayashi, Y Murakawa, ... Scientific reports 9 (1), 7122, 2019 | 33 | 2019 |
| A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron R Maeda, J Fujita, Y Konishi, Y Kazuma, H Yamazaki, I Anzai, ... Communications Biology 5 (1), 669, 2022 | 26 | 2022 |
| Protein kinase A inhibits tumor mutator APOBEC3B through phosphorylation T Matsumoto, K Shirakawa, M Yokoyama, H Fukuda, AD Sarca, S Koyabu, ... Scientific reports 9 (1), 8307, 2019 | 26 | 2019 |
| Clonally related diffuse large B-cell lymphoma and interdigitating dendritic cell sarcoma sharing MYC translocation Y Ochi, N Hiramoto, T Yoshizato, Y Ono, J Takeda, Y Shiozawa, ... Haematologica 103 (11), e553, 2018 | 18 | 2018 |
| APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression H Yamazaki, K Shirakawa, T Matsumoto, Y Kazuma, H Matsui, ... PloS one 15 (1), e0223463, 2020 | 16 | 2020 |
| APOBEC3B is preferentially expressed at the G2/M phase of cell cycle S Hirabayashi, K Shirakawa, Y Horisawa, T Matsumoto, H Matsui, ... Biochemical and biophysical research communications 546, 178-184, 2021 | 15 | 2021 |
| Monitoring fusion kinetics of viral and target cell membranes in living cells using a SARS-CoV-2 spike-protein-mediated membrane fusion assay H Nasser, R Shimizu, J Ito, K Matsuno, N Nao, H Sawa, M Kishimoto, ... STAR protocols 3 (4), 101773, 2022 | 14 | 2022 |
| Genotype to Phenotype Japan A Saito, T Irie, R Suzuki, T Maemura, H Nasser, K Uriu, Y Kosugi, ... C., Tanaka, S., Nakagawa, S., Ikeda, T., Fukuhara, T., Kawaoka, Y. & Sato, K, 2021 | 13 | 2021 |
| Characterization of the immune resistance of severe acute respiratory syndrome coronavirus 2 Mu variant and the robust immunity induced by Mu infection K Uriu, P Cárdenas, E Muñoz, V Barragan, Y Kosugi, K Shirakawa, ... The Journal of Infectious Diseases 226 (7), 1200-1203, 2022 | 12 | 2022 |
| SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance. bioRxiv 2021 I Kimura, Y Kosugi, J Wu, D Yamasoba, EP Butlertanaka, YL Tanaka, ... Google Scholar, 0 | 11 | |
| SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance (preprint) I Kimura, Y Kosugi, J Wu, D Yamasoba, EP Butlertanaka, YL Tanaka, ... | 10 | 2021 |
| Genotype to Phenotype Japan (G2P-Japan) Consortium. 2022. The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance. Cell Rep 38: 110218 I Kimura, Y Kosugi, J Wu, J Zahradnik, D Yamasoba, EP Butlertanaka, ... | 8 | 2021 |
